JUSH Jushi Holdings Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1909747 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.2%
TTM net income YoY15.7%
TTM EPS YoY15.2%
Revenue 3-yr CAGR-0.2%
Net income 3-yr CAGR—
Margins
Gross margin44.2%
Operating margin2.4%
Net margin-20.0%
FCF margin2.2%
EBITDA margin11.1%
Returns
ROE—
ROA-12.9%
ROIC (approx.)8.6%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets136.3%
Debt / equity—
Current ratio0.79x
Interest coverage0.16x
Cash quality & payout
Operating cash flow / net income-0.34x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $262.91M | $257.52M |
| Cost of revenue | $148.93M | $139.22M |
| Gross profit | $113.98M | $118.30M |
| SG&A expense | $109.13M | $107.01M |
| Operating income | $4.85M | $10.86M |
| Interest expense | $41.30M | $37.98M |
| Income tax | $34.99M | $31.63M |
| Net income | -$68.59M | -$48.78M |
| EBITDA | $35.84M | $40.75M |
| EPS (basic) | -0.35 | -0.25 |
| EPS (diluted) | -0.35 | -0.25 |
| Weighted avg. shares (diluted) | 195.20M | 195.16M |
| Balance sheet | ||
| Cash & equivalents | $24.05M | $21.35M |
| Receivables | $2.80M | $1.46M |
| Inventory | $34.61M | $36.14M |
| Current assets | $68.31M | $72.15M |
| PP&E, net | $143.32M | $144.06M |
| Goodwill | $30.91M | $30.91M |
| Intangibles | $92.20M | $100.47M |
| Total assets | $422.34M | $440.32M |
| Current liabilities | $66.19M | $68.89M |
| Short-term debt | $6.64M | $2.76M |
| Long-term debt | $199.19M | $183.45M |
| Total debt | $205.83M | $186.21M |
| Total liabilities | $537.69M | $490.56M |
| Shareholders' equity | -$115.34M | -$50.23M |
| Net debt | $181.79M | $164.86M |
| Cash flow statement | ||
| Operating cash flow | $17.73M | $21.57M |
| Capital expenditure | $16.09M | $4.71M |
| Free cash flow | $1.64M | $16.86M |
| Investing cash flow | -$13.22M | -$7.07M |
| Financing cash flow | $767,000 | -$24.46M |
| Depreciation & amortization | $30.99M | $29.89M |
| Stock-based compensation | $2.10M | $4.22M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.